Penny Share Can Skyrocket

last updated on

Penny Share Can Skyrocket

This Penny Share Can Skyrocket By 127%

The year 2026 is going very well for the FTSE 100 index. However, a quick look at the gains on some of the penny stocks can make the FTSE 100's returns look pale in comparison.

There's one penny stock called Poolbeg Pharma (POLB). This UK penny stock has gained 123% since the start of 2026. Now, analysts think Poolbeg Pharma has the potential to gain 127% in the next 12 months.

Poolbeg Pharma Is A Biopharma Company

Poolbeg Pharma is in the biotech business. It is a clinical-stage biopharma company that's working on solving a genuine medical need.

The lead drug of Poolbeg Pharma is POLB 001. The drug is in development and will help prevent Cytokine Release Syndrome. It is a serious and even life-threatening reaction. This is seen in more than 70% of the patients who are receiving new cancer immunotherapies.

If POLB 001 is successful, it would become easy to deliver these modern treatments in even community hospitals rather than specialized cancer hospitals. According to available data, the market opportunity is worth more than $10 billion.

As of now, the market cap of Poolbeg Pharma is 65.5 million. This puts it in the category of penny stocks. But the things Poolbeg Pharma is working on mean the upside potential is massive.

The company has already set up its first trial site for the POLB 001. In fact, the 1st patient has already been treated, which shows the drug has potential. Now, the company has set up a second site at University College London Hospital.

Considering all of these things, it is clear there's a lot to be excited about at Poolbeg Pharma. At the same time, you should know that it is a pre-revenue company. And there's a limited cash runway, which can make things difficult.

So, if you have the stomach for high volatility, then you should definitely consider the Poolbeg Pharma stock. It is a penny stock with potential to rise by more than 127%.

Trending Stories